Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Classification  





2 Gram Staining  





3 Treatment  





4 Testing On Agar  





5 Clinical relevance  





6 See also  





7 References  





8 External links  














Ureaplasma urealyticum






العربية
Català
Čeština
Deutsch
Español
Français
Galego
Italiano
مصرى
Português
Română
Русский
Slovenščina
Srpskohrvatski / српскохрватски
Svenska
Українська
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 

(Redirected from Ureaplasma infection)

Ureaplasma urealyticum
A number of medium-sized, Ureaplasma urealyticum colonies, otherwise known as T-strain mycoplasma, under magnification of 500×
Scientific classification Edit this classification
Domain: Bacteria
Phylum: Mycoplasmatota
Class: Mollicutes
Order: Mycoplasmatales
Family: Mycoplasmataceae
Genus: Ureaplasma
Species:
U. urealyticum
Binomial name
Ureaplasma urealyticum

Shepard et al. 1974 (Approved Lists 1980)

Ureaplasma urealyticum is a bacterium belonging to the genus Ureaplasma and the family Mycoplasmataceae[1] in the order Mycoplasmatales. This family consists of the genera Mycoplasma and Ureaplasma. Its type strain is T960. There are two known biovars of this species; T960 and 27. These strains of bacteria are commonly found as commensals in the urogenital tracts of human beings, but overgrowth can lead to infections that cause the patient discomfort. Unlike most bacteria, Ureaplasma urealyticum lacks a cell wall making it unique in physiology and medical treatment.

Classification[edit]

The six recognised Ureaplasma species have a GC content of 27 to 30 percent and a genome size ranging from 0.76 to 1.17 million base pairs, and cholesterol is required for growth.[2] A defining characteristic of the genus is that they perform urea hydrolysis, which creates ammonia as a product. Some strains originally classified as U. urealyticum should be treated as a new species, U. parvum.[3] Both strains of Ureaplasma urealyticum have had their DNA sequenced, using a PCR amplification and dideoxy termination method.[4] Their sequences can be accessed through public records and databases. Most of the16S rDNA sequence of the two strains constitute the exact same nucleotides bases (97.3% homology), yet small differences have been acknowledged.[4] Due to the direct similarity and the increased variation in other species of Ureaplasma, it is thought that the two strains of Ureaplasma urealyticum (T960 and 27) have evolutionary diverged together. In the same study conducted, using the same 16s rDNA aligned sequences, they concluded all the mammalian strains diverged and coevolved with their corresponding species (canine, feline, human, bovine) during the Cretaceous period. It was found that the most closely related species strain of UreaplasmatoUreaplasma urealyticum was Ureaplasma diversum (isolated from bovine).[4]

Gram Staining[edit]

U. urealyticum represents one of the 14 distinct types within the Ureaplasma genus. Classified within the Mollicutes class, Ureaplasma species have undergone significant evolutionary adaptations from their Gram-positive bacterial ancestors, a phenomenon termed degenerative evolutions (Kallapur, Suhas G, et al 2013[2]). This evolutionary trajectory has resulted in the loss of the peptidoglycan cell wall, a hallmark characteristic of Gram-positive bacteria. Despite this evolutionary divergence, instances have been reported where U. urealyticum, upon gram staining, exhibited the same characteristics as Gram-negative bacteria. Notably, despite such staining outcomes, it is imperative to recognize that the U. urealyticum remains a Gram-Positive bacterium, This discrepancy underscores the importance of discerning between staining outcomes and bacterial classification (“Ureaplasma Urealyticum.” Microbewiki[5]).

Treatment[edit]

As stated previously, since these bacteria are still considered Gram-positive, and lack a cell wall, the most versatile antibiotic that can’t be used is penicillin. Since these antibiotics attack the cell wall of a bacterium, they can not be used for this type of infection. The reason that many individuals get this infection can be damage to the uterus wall lining, causing the bacteria to thrive in a carbon-rich environment.

Unfortunately, it was found from trials that many of the antibiotics that we utilize on a day-to-day basis for urinary tract infections do not affect the bacteria due to lacking a cell wall. Yet, the types of antibiotics that can be used are quinolones, tetracyclines, and macrolides, since they affect a large part of the mycoplasma family of bacteria where U. urealyticum falls under.

Yet, it is not recommended to be used a lot because these bacteria can develop resistance to these antibiotics fairly fast. Secondly, other drugs that have β-lactamases are infective to treat infection because of how fast the bacteria's circular genome can mutate (Fan et al. 2023[6]). However, there are new movements to use Azithromycin to treat these infections. This is a therapeutic that can be taken orally, once ingested our macrophages, which are part of our immune system, take up the antibiotic and deliver it to the sites of infection (Fan et al. 2023[7]). This helps control the infection where the bacteria grows, additionally, it is also a great alternative to when a mother is pregnant so it does not cause harm to the fetus since It's using our immune system to help defend the fetus and the mother's body.

Testing On Agar[edit]

To test for this bacterium, an agar plate, which is 10B broth, should be used on U. urealyticum. Since these bacteria love to grow in mostly acidic places, the bacteria should go under microdilution MIC dilution to get a pH color change. If the dilution color changes to red it indicates that there is presence of U. urealyticum in the sample. After this, it should be transferred to the 10B Broth, where once placed it will turn yellow, but then slowly change the color to pink. This helps to indicate the growth of the bacterium(Waites, Ken B, et al 2012[8]). The reason it can grow on this 10B Broth is because it has a lot of nutrients that let the bacteria grow from heart infusion to yeast extract, yet, it also has urea to help the bacteria to hydrolyze it and with hydrolyzing it causes the release of ammonia that causes the broth to change to a pink color (10B Broth - Thermo Fisher Scientific). The reason for this is that it loves to live in urea-rich environments. It's the same reason why in clinics, they take urine samples or vaginal swabs to be sent to the labs to run this test on 10B broth.

Clinical relevance[edit]

Ureaplasma urealyticum can cause urethritis and may cause bacterial vaginosis.[9] Infection can occur in extragenital sites.[3] A common symptom associated with these infections is the "fishy" smell that is created due to the production of ammonia by the hydrolysis of urea. Patients should confirm diagnosis with a doctor. The bacterium has high correlations with the Human Papillomavirus (HPV).[citation needed] It has also been linked to infertility in both males and females.[9] In addition, this pathogen may latently infect the chorionic villi tissues of pregnant women, thereby impacting pregnancy outcome.[5] Issues that arise from Ureaplasma urealyticum infections during pregnancy include preterm birth and impacted embryonic development. Some patients have given birth to children subjected to bronchopulmonary dysplasia, Intraventricular hemorrhage, and necrotizing enterocolitis.[10] Patients can evolve resistances to normal antibiotic treatments due to the distinctive physiology of these organisms. In the Western World, approximately 40% of Ureaplasma species are resistant to fluoroquinolones (i.e. ciprofloxacin).[6] Patients who are pregnant have further limitations on the treatment course of a Ureaplasma urealyticum infection, making it far harder to successfully cure.[citation needed]

See also[edit]

References[edit]

  1. ^ E.A. Freundt The classification of the pleuropneumonia group of organisms (Borrelomycetales) International Bulletin of Bacteriological Nomenclature and Taxonomy, 1955, 5, 67–78.] (See page 73)
  • ^ a b "Ureaplasma urealyticum- Classification". Meducation.net.
  • ^ a b "Ureaplasma Infection: Background, Pathophysiology, Epidemiology". 17 November 2017. {{cite journal}}: Cite journal requires |journal= (help)
  • ^ a b c HARASAWA, RYÒ; CASSELL, GAIL H. (1996). "Phylogenetic Analysis of Genes Coding for 16S rRNA in Mammalian Ureaplasmas". International Journal of Systematic and Evolutionary Microbiology. 46 (3): 827–829. doi:10.1099/00207713-46-3-827. ISSN 1466-5026. PMID 8782697.
  • ^ a b Contini C, Rotondo JC, Magagnoli F, Maritati M, Seraceni S, Graziano A, Poggi A, Capucci R, Vesce F, Tognon M, Martini F (2018). "Investigation on silent bacterial infections in specimens from pregnant women affected by spontaneous miscarriage". J Cell Physiol. 234 (1): 100–9107. doi:10.1002/jcp.26952. hdl:11392/2393176. PMID 30078192.
  • ^ a b Pavoni, Matteo; Principe, Luigi; Foschi, Claudio; Meroni, Elisa; Briozzo, Elena; Lazzarotto, Tiziana; Ambretti, Simone; Di Bella, Stefano (7 December 2023). "Antimicrobial Resistance of Genital Mycoplasma and Ureaplasma : A Multicentre Study Over a 5-Year Period in Italy (2017–2021)". Microbial Drug Resistance. 30: 55–60. doi:10.1089/mdr.2023.0202. ISSN 1076-6294. PMID 38060805.
  • ^ Fan, Weibin; Wang, Qisheng; Liang, Zuyu; Wang, Jinyu; Zhang, Lin (16 March 2023). "Efficacy of azithromycin in treating Ureaplasma urealyticum: a systematic review and meta-analysis". BMC Infectious Diseases. 23 (1): 163. doi:10.1186/s12879-023-08102-5. ISSN 1471-2334. PMC 10021952. PMID 36927441.
  • ^ Waites, Ken B.; Duffy, Lynn B.; Bébéar, Cécile M.; Matlow, Anne; Talkington, Deborah F.; Kenny, George E.; Totten, Patricia A.; Bade, Donald J.; Zheng, Xiaotian; Davidson, Maureen K.; Shortridge, Virginia D.; Watts, Jeffrey L.; Brown, Steven D. (November 2012). "Standardized Methods and Quality Control Limits for Agar and Broth Microdilution Susceptibility Testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum". Journal of Clinical Microbiology. 50 (11): 3542–3547. doi:10.1128/JCM.01439-12. ISSN 0095-1137. PMC 3486213. PMID 22915608.
  • ^ a b "Ureaplasma: Causes, symptoms, and treatment". Medical News Today. 26 April 2018. Retrieved 23 April 2019.
  • ^ Hillitt, K. L.; Jenkins, R. E.; Spiller, O. B.; Beeton, M. L. (2017). "Antimicrobial activity of Manuka honey against antibiotic-resistant strains of the cell wall-free bacteria Ureaplasma parvum and Ureaplasma urealyticum" (PDF). Letters in Applied Microbiology. 64 (3): 198–202. doi:10.1111/lam.12707. hdl:10369/8313. ISSN 1472-765X. PMID 27992658. S2CID 8466307.
  • External links[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Ureaplasma_urealyticum&oldid=1219126487"

    Categories: 
    Ureaplasma
    Sexually transmitted diseases and infections
    Infectious causes of cancer
    Infections with a predominantly sexual mode of transmission
    Bacterial vaginosis
    Bacteria described in 1974
    Hidden categories: 
    CS1 errors: missing periodical
    Use dmy dates from October 2023
    Articles with short description
    Short description matches Wikidata
    Articles with 'species' microformats
    All articles with unsourced statements
    Articles with unsourced statements from May 2020
    Articles with unsourced statements from April 2021
     



    This page was last edited on 15 April 2024, at 22:29 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki